Merck Sharp and Dohme
Craig earned a PhD in Chemical Engineering from the University of Delaware and was hired by Merck Sharp and Dohme (MSD) in 2001 where he became involved with technologies to enable the oral delivery of water insoluble drugs. These efforts grew into a center of excellence in 2008 which Craig led until 2014. As the center lead, Craig was responsible for charting the strategic course and leading implementation activities to enable more than 20 development products encompassing the technical objectives of ~30 scientists, more than $6M in annual external partnerships, and creation of an integrated line of sight for the technologies from discovery applications to commercial launch. These technologies enabled the successful commercialization of three drug products.
Today, Craig leads the specialty dosage formulation group responsible for the design and development of long acting implants, respiratory products and other drug-device combination products. The potential to positively impact human health and to help develop others to maximize their impact on human health through the design of new pharmaceutical products remain primary motivations in Craig's career.